Johnson & Johnson (JNJ) Financials

$153.25 +0.31 (+0.20%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$153.36 +0.11 (+0.07%)

As of 04:30 AM Eastern

Annual Income Statements for Johnson & Johnson

This table shows Johnson & Johnson's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/29/2024	12/31/2023	1/1/2023	1/2/2022	1/3/2021	12/29/2019	12/30/2018	12/31/2017	1/1/2017	1/3/2016
Net Income / (Loss) Attributable to Common Shareholders	14,066	35,153	17,941	20,878	14,714	15,119	15,297	1,300	16,540	15,409
Consolidated Net Income / (Loss)	14,066	35,153	17,941	20,878	14,714	15,119	15,297	1,300	16,540	15,409
Net Income / (Loss) Continuing Operations	14,066	13,326	16,370	17,801	14,714	15,119	15,297	1,300	16,540	15,409
Total Pre-Tax Income	16,687	15,062	19,359	19,178	16,497	17,328	17,999	17,673	19,803	19,196
Total Operating Income	20,804	21,207	19,955	19,834	19,486	19,814	19,798	18,180	20,371	17,556
Total Gross Profit	61,350	58,606	55,394	55,338	54,157	54,503	54,490	51,011	50,101	48,538
Total Revenue	88,821	85,159	79,990	78,740	82,584	82,059	81,581	76,450	71,890	70,074
Operating Revenue	88,821	85,159	79,990	78,740	82,584	82,059	81,581	76,450	71,890	70,074
Total Cost of Revenue	27,471	26,553	24,596	23,402	28,427	27,556	27,091	25,439	21,789	21,536
Operating Cost of Revenue	27,471	26,553	24,596	23,402	28,427	27,556	27,091	25,439	21,789	21,536
Total Operating Expenses	40,546	37,399	35,439	35,504	34,671	34,689	34,692	32,831	29,730	30,982
Selling, General & Admin Expense	22,869	21,512	20,246	20,118	22,084	22,178	22,540	21,520	20,067	21,203
Research & Development Expense	17,443	15,398	14,918	15,177	12,340	12,245	11,901	11,002	9,172	9,270
Restructuring Charge	234	489	275	209	247	266	251	309	491	509
Total Other Income / (Expense), net	-4,117	-6,145	-596	-656	-2,989	-2,486	-1,799	-507	-568	1,640
Interest Expense	755	772	276	183	201	318	1,005	934	726	552
Interest & Investment Income	1,332	1,261	490	53	111	357	611	385	368	128
Other Income / (Expense), net	-4,694	-6,634	-810	-526	-2,899	-2,525	-1,405	42	-210	2,064
Income Tax Expense	2,621	1,736	2,989	1,377	1,783	2,209	2,702	16,373	3,263	3,787
Net Income / (Loss) Discontinued Operations	0.00	21,827	1,571	3,077	-	-	-	-	-	-
Basic Earnings per Share	$5.84	$13.88	$6.83	$7.93	$5.59	$5.72	$5.70	$0.48	$6.04	$5.56
Weighted Average Basic Shares Outstanding	2.41B	2.53B	2.63B	2.63B	2.63B	2.65B	2.68B	2.69B	2.74B	2.77B
Diluted Earnings per Share	$5.79	$13.72	$6.73	$7.81	$5.51	$5.63	$5.61	$0.47	$5.93	$5.48
Weighted Average Diluted Shares Outstanding	2.43B	2.56B	2.66B	2.67B	2.67B	2.68B	2.73B	2.75B	2.79B	2.81B
Weighted Average Basic & Diluted Shares Outstanding	2.41B	2.41B	2.60B	2.63B	2.63B	2.63B	2.68B	2.71B	2.74B	2.77B
Cash Dividends to Common per Share	$4.91	$4.70	$4.45	$4.19	$3.98	$3.75	$3.54	$3.32	$3.15	$2.95

This table shows Johnson & Johnson's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/30/2025	12/29/2024	9/29/2024	6/30/2024	3/31/2024	12/31/2023	10/1/2023	7/2/2023	4/2/2023	1/1/2023	10/2/2022
Net Income / (Loss) Attributable to Common Shareholders	10,999	3,431	2,694	4,686	3,255	4,049	26,028	5,144	-68	3,520	4,458
Consolidated Net Income / (Loss)	10,999	3,431	2,694	4,686	3,255	4,049	26,028	5,144	-68	3,520	4,458
Net Income / (Loss) Continuing Operations	10,999	3,431	2,694	4,686	3,255	4,132	4,309	5,376	-491	2,097	4,310
Total Pre-Tax Income	13,631	3,887	3,338	5,748	3,714	4,826	5,217	6,306	-1,287	2,485	5,172
Total Operating Income	6,182	3,582	5,037	6,276	5,909	4,193	5,534	5,813	5,667	2,821	5,299
Total Gross Profit	14,536	15,392	15,508	15,578	14,872	14,597	14,745	15,057	14,207	9,641	13,824
Total Revenue	21,893	22,520	22,471	22,447	21,383	21,395	21,351	21,519	20,894	12,548	19,996
Operating Revenue	21,893	22,520	22,471	22,447	21,383	21,395	21,351	21,519	20,894	12,548	19,996
Total Cost of Revenue	7,357	7,128	6,963	6,869	6,511	6,798	6,606	6,462	6,687	2,907	6,172
Operating Cost of Revenue	7,357	7,128	6,963	6,869	6,511	6,798	6,606	6,462	6,687	2,907	6,172
Total Operating Expenses	8,354	11,810	10,471	9,302	8,963	10,404	9,211	9,244	8,540	6,820	8,525
Selling, General & Admin Expense	5,112	6,453	5,478	5,681	5,257	5,810	5,400	5,396	4,906	3,107	4,975
Marketing Expense	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Research & Development Expense	3,225	5,315	4,952	3,634	3,542	4,538	3,653	3,703	3,504	3,658	3,485
Restructuring Charge	17	42	41	-13	164	56	158	145	130	55	65
Total Other Income / (Expense), net	7,449	305	-1,699	-528	-2,195	633	-317	493	-6,954	-336	-127
Interest Expense	204	137	193	270	155	151	192	217	212	177	51
Interest & Investment Income	332	281	292	395	364	363	374	326	198	254	150
Other Income / (Expense), net	7,321	161	-1,798	-653	-2,404	421	-499	384	-6,940	-413	-226
Income Tax Expense	2,632	456	644	1,062	459	694	908	930	-796	388	862
Basic Earnings per Share	$4.57	$1.42	$1.12	$1.95	$1.35	$1.61	$10.32	$1.98	($0.03)	$1.34	$1.70
Weighted Average Basic Shares Outstanding	2.41B	2.41B	2.41B	2.41B	2.41B	2.53B	2.52B	2.60B	2.61B	2.63B	2.63B
Diluted Earnings per Share	$4.54	$1.41	$1.11	$1.93	$1.34	$1.58	$10.21	$1.96	($0.03)	$1.32	$1.68
Weighted Average Diluted Shares Outstanding	2.42B	2.43B	2.43B	2.42B	2.43B	2.56B	2.55B	2.63B	2.61B	2.66B	2.66B
Weighted Average Basic & Diluted Shares Outstanding	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B	2.60B	2.60B	2.60B	2.61B
Cash Dividends to Common per Share	$1.24	-	$1.24	$1.24	$1.19	-	$1.19	$1.19	$1.13	-	$1.13

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/29/2024	12/31/2023	1/1/2023	1/2/2022	1/3/2021	12/29/2019	12/30/2018	12/31/2017	1/1/2017	1/3/2016
Net Change in Cash & Equivalents	2,246	7,732	-360	502	-3,320	-802	524	-1,485	5,240	-791
Net Cash From Operating Activities	24,266	22,791	21,194	23,410	23,536	23,416	22,201	21,056	18,767	19,569
Net Cash From Continuing Operating Activities	24,266	22,791	21,194	23,410	23,536	23,416	22,201	21,056	18,767	19,569
Net Income / (Loss) Continuing Operations	14,066	35,153	17,941	20,878	14,714	15,119	15,297	1,300	16,540	15,409
Consolidated Net Income / (Loss)	14,066	35,153	17,941	20,878	14,714	15,119	15,297	1,300	16,540	15,409
Depreciation Expense	7,339	7,486	6,970	7,390	7,231	7,009	6,929	5,642	3,754	3,746
Non-Cash Adjustments To Reconcile Net Income	3,207	-18,161	1,957	1,459	1,190	-101	988	467	587	-945
Changes in Operating Assets and Liabilities, net	-346	-1,687	-5,674	-6,317	401	1,389	-1,013	13,647	-2,114	1,359
Net Cash From Investing Activities	-18,599	878	-12,371	-8,683	-20,825	-6,194	-3,167	-14,868	-4,761	-7,735
Net Cash From Continuing Investing Activities	-18,599	878	-12,371	-8,683	-20,825	-6,194	-3,167	-14,868	-4,761	-7,735
Purchase of Property, Plant & Equipment	-4,424	-4,543	-4,009	-3,652	-3,347	-3,498	-3,670	-3,279	-3,226	-3,463
Acquisitions	-16,929	-470	-17,652	-60	-7,323	-5,810	-899	-35,151	-4,509	-954
Purchase of Investments	-1,726	-10,906	-32,384	-30,394	-21,089	-3,920	-5,626	-6,153	-33,950	-40,828
Sale of Property, Plant & Equipment	675	358	543	711	305	3,265	3,203	1,832	1,267	3,464
Sale and/or Maturity of Investments	2,462	19,390	41,609	25,006	12,137	3,387	4,289	28,117	35,780	34,149
Other Investing Activities, net	1,343	-2,951	-478	-294	-1,508	382	-464	-234	-123	-103
Net Cash From Financing Activities	-3,132	-15,825	-8,871	-14,047	-6,120	-18,015	-18,510	-7,673	-8,551	-11,136
Net Cash From Continuing Financing Activities	-3,132	-15,825	-8,871	-14,047	-6,120	-18,015	-18,510	-7,673	-8,551	-11,136
Repayment of Debt	-10,954	-16,746	-8,591	-2,878	-4,021	-2,448	-4,207	-3,295	-4,255	-1,169
Repurchase of Common Equity	-2,432	-5,054	-6,035	-3,456	-3,221	-6,746	-5,868	-6,358	-8,979	-5,290
Payment of Dividends	-11,823	-11,770	-11,682	-11,032	-10,481	-9,917	-9,494	-8,943	-8,621	-8,173
Issuance of Debt	21,937	13,743	16,136	2,002	10,822	42	85	9,861	12,115	2,491
Issuance of Common Equity	0.00	4,241	0.00	0.00	-	-	-	-	-	-
Other Financing Activities, net	140	-239	1,301	1,317	781	1,054	974	1,062	1,189	1,005
Effect of Exchange Rate Changes	-289	-112	-312	-178	89	-9.00	-	-	-215	-1,489
Cash Interest Paid	3,901	3,602	1,915	1,931	1,745	1,920	2,012	1,826	1,358	1,132
Cash Income Taxes Paid	6,714	8,574	5,223	4,768	4,619	4,191	4,570	3,312	2,843	2,865

This table details how cash moves in and out of Johnson & Johnson's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/30/2025	12/29/2024	9/29/2024	6/30/2024	3/31/2024	12/31/2023	10/1/2023	7/2/2023	4/2/2023	1/1/2023	10/2/2022
Net Change in Cash & Equivalents	14,369	4,125	-4,898	-595	3,614	2,131	-1,455	-5,682	12,738	2,772	372
Net Cash From Operating Activities	4,174	6,983	7,993	5,633	3,657	7,863	7,489	4,182	3,257	5,350	6,284
Net Cash From Continuing Operating Activities	4,174	6,983	7,993	5,633	3,657	7,863	7,489	4,182	3,257	5,350	6,284
Net Income / (Loss) Continuing Operations	10,999	3,431	2,694	4,686	3,255	4,049	26,028	5,144	-68	3,520	4,458
Consolidated Net Income / (Loss)	10,999	3,431	2,694	4,686	3,255	4,049	26,028	5,144	-68	3,520	4,458
Depreciation Expense	1,772	1,896	1,846	1,782	1,815	1,843	1,829	1,934	1,880	1,772	1,685
Non-Cash Adjustments To Reconcile Net Income	255	874	1,534	312	487	1,136	-20,326	1,847	-818	472	310
Changes in Operating Assets and Liabilities, net	-8,852	782	1,919	-1,147	-1,900	835	-42	-4,743	2,263	-414	-169
Net Cash From Investing Activities	-297	-1,320	-3,128	-13,687	-464	-1,202	2,541	-3,776	3,315	-4,397	-1,701
Net Cash From Continuing Investing Activities	-297	-1,320	-3,128	-13,687	-464	-1,202	2,541	-3,776	3,315	-4,397	-1,701
Purchase of Property, Plant & Equipment	-795	-1,612	-1,029	-976	-807	-1,589	-967	-1,124	-863	-1,587	-952
Acquisitions	0.00	-1,784	-338	-12,996	-1,811	-470	-	-	0.00	-17,130	1.00
Purchase of Investments	-251	-262	-280	-554	-630	-925	-293	-5,914	-3,774	-1,221	-9,115
Sale of Property, Plant & Equipment	279	52	50	363	210	121	121	76	40	221	8.00
Sale and/or Maturity of Investments	218	290	466	727	979	3,603	3,910	4,111	7,766	15,285	8,690
Other Investing Activities, net	252	1,996	-1,997	-251	1,595	-1,942	-230	-925	146	35	-333
Net Cash From Financing Activities	10,422	-1,340	-9,882	7,544	546	-4,655	-11,317	-5,991	6,138	1,700	-3,925
Net Cash From Continuing Financing Activities	10,422	-1,340	-9,882	7,544	546	-4,655	-11,317	-5,991	6,138	1,700	-3,925
Repayment of Debt	-2,831	-1,758	-4,515	-3,883	-798	-2,761	180	-8,038	-6,127	-1,778	-2,469
Repurchase of Common Equity	-2,127	-282	-539	-136	-1,475	-216	-920	-381	-3,537	-1,320	-2,165
Payment of Dividends	-2,989	-2,984	-2,985	-2,985	-2,869	-2,865	-2,871	-3,092	-2,942	-2,954	-2,970
Issuance of Debt	17,922	3,293	-1,991	15,370	5,265	1,281	-7,433	1,127	18,768	9,036	2,727
Other Financing Activities, net	447	391	148	-822	423	-94	-273	152	-24	-1,284	952
Effect of Exchange Rate Changes	70	-198	119	-85	-125	125	-168	-97	28	119	-286

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/29/2024	12/31/2023	1/1/2023	1/2/2022	1/3/2021	12/29/2019	12/30/2018	12/31/2017	1/1/2017	1/3/2016
Total Assets	180,104	167,558	187,378	182,018	174,894	157,728	152,954	157,303	141,208	133,411
Total Current Assets	55,893	53,495	55,294	60,979	51,237	45,274	46,033	43,088	65,032	60,210
Cash & Equivalents	24,105	21,859	12,889	14,487	13,985	17,305	18,107	17,824	18,972	13,732
Short-Term Investments	417	1,068	9,392	17,121	11,200	1,982	1,580	472	22,935	24,644
Accounts Receivable	14,842	14,873	14,039	15,283	13,576	14,481	14,098	13,490	11,699	10,734
Inventories, net	12,444	11,181	10,268	10,387	9,344	9,020	8,599	8,765	8,144	8,053
Prepaid Expenses	4,085	4,514	2,876	3,701	3,132	2,392	2,699	2,537	3,282	3,047
Plant, Property, & Equipment, net	20,518	19,898	17,982	18,962	18,766	17,658	17,035	17,005	15,912	15,905
Total Noncurrent Assets	103,693	94,165	114,102	102,077	104,891	94,796	89,886	97,210	60,264	57,296
Goodwill	44,200	36,558	36,047	35,246	36,393	33,639	30,453	31,906	22,805	21,629
Intangible Assets	37,618	34,175	38,489	46,392	53,402	47,643	47,611	53,228	26,876	25,764
Noncurrent Deferred & Refundable Income Taxes	10,461	9,279	8,947	10,223	8,534	7,819	7,640	7,105	6,148	5,490
Other Noncurrent Operating Assets	11,414	14,153	9,212	10,216	6,562	5,695	4,182	4,971	4,435	4,413
Total Liabilities & Shareholders' Equity	180,104	167,558	187,378	182,018	174,894	157,728	152,954	157,303	141,208	133,411
Total Liabilities	108,614	98,784	110,574	107,995	111,616	98,257	93,202	97,143	70,790	62,261
Total Current Liabilities	50,321	46,282	55,802	45,226	42,493	35,964	31,230	30,537	26,287	27,747
Short-Term Debt	5,983	3,451	12,756	3,766	2,631	1,202	2,796	3,906	4,684	7,004
Accounts Payable	10,311	9,632	9,889	11,055	9,505	8,544	7,537	7,310	6,918	6,668
Accrued Expenses	26,129	26,213	24,298	25,707	25,481	20,598	16,981	14,514	11,038	10,851
Current Deferred & Payable Income Tax Liabilities	3,772	2,993	2,220	1,112	1,392	2,266	818	1,854	971	750
Current Employee Benefit Liabilities	4,126	3,993	3,049	3,586	3,484	3,354	3,098	2,953	2,676	2,474
Total Noncurrent Liabilities	58,293	52,502	54,772	62,769	69,123	62,293	61,972	66,606	44,503	34,514
Long-Term Debt	30,651	25,881	26,886	29,985	32,635	26,494	27,684	30,675	22,442	12,857
Noncurrent Deferred Revenue	390	2,881	4,306	5,713	6,559	7,444	8,242	8,472	0.00	-
Noncurrent Deferred & Payable Income Tax Liabilities	2,448	3,193	3,991	7,487	7,214	5,958	7,506	8,368	2,910	2,562
Noncurrent Employee Benefit Liabilities	7,255	7,149	6,542	8,898	10,771	10,663	9,951	10,074	9,615	8,854
Other Noncurrent Operating Liabilities	17,549	13,398	10,146	10,686	11,944	11,734	8,589	9,017	9,536	10,241
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-
Total Equity & Noncontrolling Interests	71,490	68,774	76,804	74,023	63,278	59,471	59,752	60,160	70,418	71,150
Total Preferred & Common Equity	71,490	68,774	76,804	74,023	63,278	59,471	59,752	60,160	70,418	71,150
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	71,490	68,774	76,804	74,023	63,278	59,471	59,752	60,160	70,418	71,150
Common Stock	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120
Retained Earnings	155,791	153,843	128,345	123,060	113,890	110,659	106,216	101,793	110,551	103,879
Treasury Stock	-75,680	-75,662	-41,694	-39,099	-38,490	-38,417	-34,362	-31,554	-28,352	-22,684
Accumulated Other Comprehensive Income / (Loss)	-11,741	-12,527	-12,967	-13,058	-15,242	-15,891	-15,222	-13,199	-14,901	-13,165

This table presents Johnson & Johnson's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/30/2025	12/29/2024	9/29/2024	6/30/2024	3/31/2024	12/31/2023	10/1/2023	7/2/2023	4/2/2023	1/1/2023	10/2/2022
Total Assets	193,671	180,104	178,287	181,088	171,966	167,558	166,061	191,686	195,969	187,378	175,124
Total Current Assets	71,551	55,893	53,249	57,817	57,002	53,495	53,703	60,567	64,388	55,294	65,236
Cash & Equivalents	38,474	24,105	19,980	24,878	25,473	21,859	19,728	21,183	19,170	12,889	11,355
Short-Term Investments	307	417	317	597	745	1,068	3,783	7,322	5,443	9,392	22,724
Accounts Receivable	16,020	14,842	16,174	15,794	14,946	14,873	14,798	16,777	16,350	14,039	15,890
Inventories, net	12,659	12,444	12,603	12,169	11,383	11,181	11,198	12,888	12,809	10,268	11,675
Prepaid Expenses	4,091	4,085	4,175	4,379	4,455	4,514	4,196	2,397	2,921	2,876	3,592
Plant, Property, & Equipment, net	20,871	20,518	20,479	19,748	19,632	19,898	18,821	20,576	20,174	17,982	18,152
Plant, Property & Equipment, gross	49,884	-	49,274	48,035	47,585	-	45,626	51,218	50,367	-	46,681
Accumulated Depreciation	29,013	-	28,795	28,287	27,953	-	26,805	30,642	30,193	-	28,529
Total Noncurrent Assets	101,249	103,693	104,559	103,523	95,332	94,165	93,537	110,543	111,407	114,102	91,736
Goodwill	44,468	44,200	44,799	44,250	36,616	36,558	36,124	45,440	45,575	36,047	33,383
Intangible Assets	36,755	37,618	39,490	39,725	34,286	34,175	35,021	46,246	47,448	38,489	40,336
Noncurrent Deferred & Refundable Income Taxes	8,492	10,461	9,349	9,004	10,305	9,279	9,259	8,779	8,817	8,947	9,392
Other Noncurrent Operating Assets	11,534	11,414	10,921	10,544	14,125	14,153	13,133	10,078	9,567	9,212	8,625
Total Liabilities & Shareholders' Equity	193,671	180,104	178,287	181,088	171,966	167,558	166,061	191,686	195,969	187,378	175,124
Total Liabilities	115,562	108,614	108,129	109,550	101,946	98,784	94,833	115,277	125,100	110,574	100,525
Total Current Liabilities	56,903	50,321	51,759	53,933	48,725	46,282	44,370	54,170	60,373	55,802	45,543
Short-Term Debt	13,897	5,983	4,462	9,855	8,550	3,451	3,870	11,701	17,979	12,756	4,424
Accounts Payable	9,545	10,311	8,954	8,848	8,174	9,632	8,355	10,443	9,909	9,889	10,153
Accrued Expenses	26,693	26,129	29,889	28,078	26,505	26,213	25,909	26,277	25,988	24,298	25,974
Current Deferred & Payable Income Tax Liabilities	4,217	3,772	4,834	4,309	3,318	2,993	2,899	2,687	4,266	2,220	1,986
Current Employee Benefit Liabilities	2,551	4,126	3,620	2,843	2,178	3,993	3,337	3,062	2,231	3,049	3,006
Total Noncurrent Liabilities	58,659	58,293	56,370	55,617	53,221	52,502	50,463	61,107	64,727	54,772	54,982
Long-Term Debt	38,355	30,651	31,289	31,636	25,082	25,881	26,051	33,901	34,928	26,886	27,603
Noncurrent Deferred Revenue	395	390	354	341	2,881	2,881	2,540	2,536	4,296	4,306	4,162
Noncurrent Deferred & Payable Income Tax Liabilities	2,428	2,448	2,952	2,635	3,172	3,193	2,623	3,627	4,417	3,991	4,946
Noncurrent Employee Benefit Liabilities	7,046	7,255	6,852	6,919	7,019	7,149	5,687	6,461	6,665	6,542	8,353
Other Noncurrent Operating Liabilities	10,435	17,549	14,923	14,086	15,067	13,398	13,562	14,582	14,421	10,146	9,918
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	78,109	71,490	70,158	71,538	70,020	68,774	71,228	76,409	70,869	76,804	74,599
Total Preferred & Common Equity	78,109	71,490	70,158	71,538	70,020	68,774	71,228	75,149	70,869	76,804	74,599
Total Common Equity	78,109	71,490	70,158	71,538	70,020	68,774	71,228	75,149	70,869	76,804	74,599
Common Stock	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120
Retained Earnings	162,635	155,791	155,179	155,360	153,378	153,843	152,536	129,381	124,558	128,345	127,917
Accumulated Other Comprehensive Income / (Loss)	-11,740	-11,741	-12,522	-11,253	-10,768	-12,527	-8,780	-13,135	-12,626	-12,967	-15,292
Other Equity Adjustments	-75,906	-	-75,619	-75,689	-75,710	-	-75,648	-44,217	-44,183	-	-

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/29/2024	12/31/2023	1/1/2023	1/2/2022	1/3/2021	12/29/2019	12/30/2018	12/31/2017	1/1/2017	1/3/2016
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.30%	6.46%	1.59%	-4.65%	0.64%	0.59%	6.71%	6.34%	2.59%	-5.73%
EBITDA Growth	6.30%	-15.53%	-2.18%	12.09%	-1.98%	-4.04%	6.11%	-0.21%	2.35%	-6.25%
EBIT Growth	10.55%	-23.88%	-0.84%	16.40%	-4.06%	-6.00%	0.94%	-9.62%	2.76%	-6.70%
NOPAT Growth	-6.54%	11.19%	-8.34%	5.93%	0.53%	2.75%	1,158.21%	-92.14%	20.73%	-15.30%
Net Income Growth	-59.99%	95.94%	-14.07%	41.89%	-2.68%	-1.16%	1,076.69%	-92.14%	7.34%	-5.60%
EPS Growth	-57.80%	103.86%	-13.83%	41.74%	-2.13%	0.36%	1,093.62%	-92.07%	8.21%	-3.86%
Operating Cash Flow Growth	6.47%	7.54%	-9.47%	-0.54%	0.51%	5.47%	5.44%	12.20%	-4.10%	4.59%
Free Cash Flow Firm Growth	-46.40%	-13.34%	25.75%	32.15%	-38.17%	-19.34%	221.60%	-238.95%	-16.99%	-30.36%
Invested Capital Growth	11.20%	2.40%	-3.61%	3.83%	8.22%	-2.60%	-8.96%	37.40%	5.70%	-5.03%
Revenue Q/Q Growth	1.28%	11.59%	3.60%	-13.89%	2.14%	0.43%	0.24%	2.81%	0.41%	-0.63%
EBITDA Q/Q Growth	-3.37%	11.51%	4.20%	-1.96%	-9.07%	4.86%	1.17%	-3.42%	2.42%	4.86%
EBIT Q/Q Growth	-5.13%	17.84%	6.23%	-2.21%	-13.10%	6.44%	2.38%	-8.34%	2.77%	5.60%
NOPAT Q/Q Growth	-2.26%	6.57%	3.89%	-10.68%	-0.71%	0.51%	937.45%	-91.64%	8.77%	-7.01%
Net Income Q/Q Growth	-4.21%	1.53%	-6.35%	16.77%	-13.38%	6.84%	892.02%	-91.79%	3.76%	4.72%
EPS Q/Q Growth	-2.85%	1.93%	-6.27%	16.74%	-13.36%	7.24%	867.24%	-91.84%	4.22%	4.78%
Operating Cash Flow Q/Q Growth	-3.50%	12.39%	-1.77%	-10.03%	9.01%	0.66%	0.63%	-2.54%	9.12%	2.52%
Free Cash Flow Firm Q/Q Growth	-8.57%	35.87%	16.14%	-16.87%	-23.50%	-21.82%	31.38%	-10.64%	35.84%	-15.64%
Invested Capital Q/Q Growth	-2.35%	-3.17%	1.20%	4.05%	2.80%	-2.17%	-9.04%	-17.73%	-6.22%	-2.52%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.07%	68.82%	69.25%	70.28%	65.58%	66.42%	66.79%	66.72%	69.69%	69.27%
EBITDA Margin	26.40%	25.90%	32.65%	33.91%	28.84%	29.61%	31.04%	31.22%	33.27%	33.34%
Operating Margin	23.42%	24.90%	24.95%	25.19%	23.60%	24.15%	24.27%	23.78%	28.34%	25.05%
EBIT Margin	18.14%	17.11%	23.93%	24.52%	20.09%	21.07%	22.55%	23.84%	28.04%	28.00%
Profit (Net Income) Margin	15.84%	41.28%	22.43%	26.52%	17.82%	18.42%	18.75%	1.70%	23.01%	21.99%
Tax Burden Percent	84.29%	233.39%	92.68%	108.86%	89.19%	87.25%	84.99%	7.36%	83.52%	80.27%
Interest Burden Percent	103.58%	103.36%	101.12%	99.33%	99.46%	100.23%	97.86%	96.99%	98.22%	97.84%
Effective Tax Rate	15.71%	11.53%	15.44%	7.18%	10.81%	12.75%	15.01%	92.64%	16.48%	19.73%
Return on Invested Capital (ROIC)	22.09%	25.25%	22.56%	24.62%	24.63%	25.17%	23.04%	2.02%	31.43%	26.08%
ROIC Less NNEP Spread (ROIC-NNEP)	-15.39%	1,110.70%	-149.26%	65.01%	-4.36%	1.28%	11.34%	-2.93%	34.28%	18.07%
Return on Net Nonoperating Assets (RNNOA)	-2.03%	23.04%	1.23%	5.79%	-0.65%	0.19%	2.47%	-0.03%	-8.06%	-4.21%
Return on Equity (ROE)	20.06%	48.29%	23.79%	30.41%	23.97%	25.36%	25.51%	1.99%	23.37%	21.87%
Cash Return on Invested Capital (CROIC)	11.48%	22.88%	26.23%	20.87%	16.73%	27.80%	32.42%	-29.48%	25.88%	31.24%
Operating Return on Assets (OROA)	9.27%	8.21%	10.37%	10.82%	9.97%	11.13%	11.86%	12.21%	14.68%	14.88%
Return on Assets (ROA)	8.09%	19.81%	9.71%	11.70%	8.85%	9.73%	9.86%	0.87%	12.05%	11.68%
Return on Common Equity (ROCE)	20.06%	48.29%	23.79%	30.41%	23.97%	25.36%	25.51%	1.99%	23.37%	21.87%
Return on Equity Simple (ROE_SIMPLE)	19.68%	51.11%	23.36%	28.20%	23.25%	25.42%	25.60%	2.16%	23.49%	21.66%
Net Operating Profit after Tax (NOPAT)	17,536	18,763	16,874	18,410	17,380	17,288	16,826	1,337	17,014	14,093
NOPAT Margin	19.74%	22.03%	21.10%	23.38%	21.05%	21.07%	20.62%	1.75%	23.67%	20.11%
Net Nonoperating Expense Percent (NNEP)	37.48%	-1,085.45%	171.82%	-40.38%	28.98%	23.89%	11.70%	4.96%	-2.85%	8.02%
Return On Investment Capital (ROIC_SIMPLE)	16.22%	19.13%	14.49%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	30.93%	31.18%	30.75%	29.72%	34.42%	33.58%	33.21%	33.28%	30.31%	30.73%
SG&A Expenses to Revenue	25.75%	25.26%	25.31%	25.55%	26.74%	27.03%	27.63%	28.15%	27.91%	30.26%
R&D to Revenue	19.64%	18.08%	18.65%	19.27%	14.94%	14.92%	14.59%	14.39%	12.76%	13.23%
Operating Expenses to Revenue	45.65%	43.92%	44.30%	45.09%	41.98%	42.27%	42.52%	42.94%	41.35%	44.21%
Earnings before Interest and Taxes (EBIT)	16,110	14,573	19,145	19,308	16,587	17,289	18,393	18,222	20,161	19,620
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	23,449	22,059	26,115	26,698	23,818	24,298	25,322	23,864	23,915	23,366
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.89	5.32	5.66	5.66	5.95	5.70	4.91	5.22	3.63	3.17
Price to Tangible Book Value (P/TBV)	0.00	0.00	191.57	0.00	0.00	0.00	0.00	0.00	12.33	9.49
Price to Revenue (P/Rev)	3.93	4.29	5.43	5.33	4.56	4.13	3.60	4.11	3.56	3.22
Price to Earnings (P/E)	24.83	10.40	24.22	20.08	25.57	22.43	19.19	241.73	15.46	14.64
Dividend Yield	3.39%	3.09%	2.68%	2.63%	2.78%	2.91%	3.23%	2.84%	3.35%	3.62%
Earnings Yield	4.03%	9.61%	4.13%	4.98%	3.91%	4.46%	5.21%	0.41%	6.47%	6.83%
Enterprise Value to Invested Capital (EV/IC)	4.32	4.95	6.15	5.53	5.27	5.13	4.37	4.32	4.33	3.93
Enterprise Value to Revenue (EV/Rev)	4.07	4.37	5.65	5.35	4.68	4.24	3.73	4.32	3.35	2.95
Enterprise Value to EBITDA (EV/EBITDA)	15.41	16.87	17.30	15.79	16.22	14.30	12.02	13.85	10.08	8.86
Enterprise Value to EBIT (EV/EBIT)	22.43	25.54	23.60	21.83	23.29	20.10	16.54	18.14	11.95	10.55
Enterprise Value to NOPAT (EV/NOPAT)	20.61	19.83	26.78	22.89	22.23	20.10	18.09	247.16	14.16	14.69
Enterprise Value to Operating Cash Flow (EV/OCF)	14.89	16.33	21.32	18.00	16.41	14.84	13.71	15.70	12.84	10.58
Enterprise Value to Free Cash Flow (EV/FCFF)	39.65	21.89	23.03	27.01	32.72	18.20	12.85	0.00	17.20	12.26
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.51	0.43	0.52	0.46	0.56	0.47	0.51	0.57	0.39	0.28
Long-Term Debt to Equity	0.43	0.38	0.35	0.41	0.52	0.45	0.46	0.51	0.32	0.18
Financial Leverage	0.13	0.02	-0.01	0.09	0.15	0.15	0.22	0.01	-0.24	-0.23
Leverage Ratio	2.48	2.44	2.45	2.60	2.71	2.61	2.59	2.29	1.94	1.87
Compound Leverage Factor	2.57	2.52	2.48	2.58	2.70	2.61	2.53	2.22	1.91	1.83
Debt to Total Capital	33.88%	29.90%	34.04%	31.32%	35.79%	31.77%	33.78%	36.50%	27.81%	21.82%
Short-Term Debt to Total Capital	5.53%	3.52%	10.95%	3.49%	2.67%	1.38%	3.10%	4.12%	4.80%	7.70%
Long-Term Debt to Total Capital	28.35%	26.38%	23.09%	27.82%	33.12%	30.39%	30.68%	32.38%	23.01%	14.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	66.12%	70.10%	65.96%	68.68%	64.21%	68.23%	66.22%	63.50%	72.19%	78.18%
Debt to EBITDA	1.56	1.33	1.52	1.26	1.48	1.14	1.20	1.45	1.13	0.85
Net Debt to EBITDA	0.52	0.29	0.66	0.08	0.42	0.35	0.43	0.68	-0.62	-0.79
Long-Term Debt to EBITDA	1.31	1.17	1.03	1.12	1.37	1.09	1.09	1.29	0.94	0.55
Debt to NOPAT	2.09	1.56	2.35	1.83	2.03	1.60	1.81	25.86	1.59	1.41
Net Debt to NOPAT	0.69	0.34	1.03	0.12	0.58	0.49	0.64	12.18	-0.87	-1.31
Long-Term Debt to NOPAT	1.75	1.38	1.59	1.63	1.88	1.53	1.65	22.94	1.32	0.91
Altman Z-Score	3.97	4.35	4.08	4.16	3.78	4.01	3.91	3.81	4.57	4.57
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.11	1.16	0.99	1.35	1.21	1.26	1.47	1.41	2.47	2.17
Quick Ratio	0.78	0.82	0.65	1.04	0.91	0.94	1.08	1.04	2.04	1.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	9,113	17,003	19,621	15,603	11,807	19,097	23,676	-19,471	14,012	16,881
Operating Cash Flow to CapEx	647.27%	544.59%	611.48%	795.99%	773.70%	10,049.79%	4,753.96%	1,455.15%	957.99%	0.00%
Free Cash Flow to Firm to Interest Expense	12.07	22.02	71.09	85.26	58.74	60.05	23.56	-20.85	19.30	30.58
Operating Cash Flow to Interest Expense	32.14	29.52	76.79	127.92	117.09	73.64	22.09	22.54	25.85	35.45
Operating Cash Flow Less CapEx to Interest Expense	27.17	24.10	64.23	111.85	101.96	72.90	21.63	20.99	23.15	35.45
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.48	0.43	0.44	0.50	0.53	0.53	0.51	0.52	0.53
Accounts Receivable Turnover	5.98	5.89	5.46	5.46	5.89	5.74	5.91	6.07	6.41	6.45
Inventory Turnover	2.33	2.48	2.38	2.37	3.10	3.13	3.12	3.01	2.69	2.65
Fixed Asset Turnover	4.40	4.50	4.33	4.17	4.53	4.73	4.79	4.65	4.52	4.38
Accounts Payable Turnover	2.76	2.72	2.35	2.28	3.15	3.43	3.65	3.58	3.21	3.01
Days Sales Outstanding (DSO)	61.06	61.96	66.90	66.89	62.00	63.56	61.72	60.13	56.95	56.56
Days Inventory Outstanding (DIO)	156.95	147.42	153.26	153.87	117.90	116.69	116.97	121.31	135.66	137.60
Days Payable Outstanding (DPO)	132.49	134.17	155.40	160.34	115.87	106.50	100.02	102.07	113.79	121.19
Cash Conversion Cycle (CCC)	85.52	75.21	64.75	60.42	64.02	73.75	78.67	79.36	78.82	72.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	83,602	75,179	73,419	76,166	73,359	67,786	69,595	76,445	55,637	52,635
Invested Capital Turnover	1.12	1.15	1.07	1.05	1.17	1.19	1.12	1.16	1.33	1.30
Increase / (Decrease) in Invested Capital	8,423	1,760	-2,747	2,807	5,573	-1,809	-6,850	20,808	3,002	-2,788
Enterprise Value (EV)	361,338	372,143	451,852	421,449	386,341	347,556	304,303	330,529	240,973	207,028
Market Capitalization	349,226	365,738	434,491	419,306	376,260	339,147	293,510	314,244	255,754	225,543
Book Value per Share	$29.69	$28.57	$29.38	$28.12	$24.04	$22.60	$22.28	$22.39	$25.88	$25.71
Tangible Book Value per Share	($4.29)	($0.81)	$0.87	($2.89)	($10.07)	($8.29)	($6.83)	($9.30)	$7.62	$8.59
Total Capital	108,124	98,106	116,446	107,774	98,544	87,167	90,232	94,741	97,544	91,011
Total Debt	36,634	29,332	39,642	33,751	35,266	27,696	30,480	34,581	27,126	19,861
Total Long-Term Debt	30,651	25,881	26,886	29,985	32,635	26,494	27,684	30,675	22,442	12,857
Net Debt	12,112	6,405	17,361	2,143	10,081	8,409	10,793	16,285	-14,781	-18,515
Capital Expenditures (CapEx)	3,749	4,185	3,466	2,941	3,042	233	467	1,447	1,959	-1.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-12,967	-12,263	-10,033	-12,089	-13,810	-8,775	-2,088	-1,839	1,522	1,091
Debt-free Net Working Capital (DFNWC)	11,555	10,664	12,248	19,519	11,375	10,512	17,599	16,457	43,429	39,467
Net Working Capital (NWC)	5,572	7,213	-508	15,753	8,744	9,310	14,803	12,551	38,745	32,463
Net Nonoperating Expense (NNE)	3,470	-16,390	-1,067	-2,468	2,666	2,169	1,529	37	474	-1,316
Net Nonoperating Obligations (NNO)	12,112	6,405	-3,385	2,143	10,081	8,315	9,843	16,285	-14,781	-18,515
Total Depreciation and Amortization (D&A)	7,339	7,486	6,970	7,390	7,231	7,009	6,929	5,642	3,754	3,746
Debt-free, Cash-free Net Working Capital to Revenue	-14.60%	-14.40%	-12.54%	-15.35%	-16.72%	-10.69%	-2.56%	-2.41%	2.12%	1.56%
Debt-free Net Working Capital to Revenue	13.01%	12.52%	15.31%	24.79%	13.77%	12.81%	21.57%	21.53%	60.41%	56.32%
Net Working Capital to Revenue	6.27%	8.47%	-0.64%	20.01%	10.59%	11.35%	18.15%	16.42%	53.89%	46.33%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$5.84	$13.88	$6.83	$7.93	$5.59	$5.72	$0.00	$0.48	$6.04	$5.56
Adjusted Weighted Average Basic Shares Outstanding	2.41B	2.53B	2.63B	2.63B	2.63B	2.65B	0.00	2.69B	2.74B	2.77B
Adjusted Diluted Earnings per Share	$5.79	$13.72	$6.73	$7.81	$5.51	$5.63	$0.00	$0.47	$5.93	$5.48
Adjusted Weighted Average Diluted Shares Outstanding	2.43B	2.56B	2.66B	2.67B	2.67B	2.68B	0.00	2.75B	2.79B	2.81B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.41B	2.41B	2.60B	2.63B	2.63B	2.63B	0.00	2.68B	2.71B	2.76B
Normalized Net Operating Profit after Tax (NOPAT)	17,734	19,195	17,107	18,604	17,600	17,520	17,039	12,942	17,425	14,501
Normalized NOPAT Margin	19.97%	22.54%	21.39%	23.63%	21.31%	21.35%	20.89%	16.93%	24.24%	20.69%
Pre Tax Income Margin	18.79%	17.69%	24.20%	24.36%	19.98%	21.12%	22.06%	23.12%	27.55%	27.39%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	21.34	18.88	69.37	105.51	82.52	54.37	18.30	19.51	27.77	35.54
NOPAT to Interest Expense	23.23	24.30	61.14	100.60	86.47	54.37	16.74	1.43	23.44	25.53
EBIT Less CapEx to Interest Expense	16.37	13.46	56.81	89.44	67.39	53.64	17.84	17.96	25.07	35.55
NOPAT Less CapEx to Interest Expense	18.26	18.88	48.58	84.53	71.33	53.63	16.28	-0.12	20.74	25.53
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	84.05%	33.48%	65.11%	52.84%	71.23%	65.59%	62.06%	687.92%	52.12%	53.04%
Augmented Payout Ratio	101.34%	47.86%	98.75%	69.39%	93.12%	110.21%	100.42%	1,177.00%	106.41%	87.37%

This table displays calculated financial ratios and metrics derived from Johnson & Johnson's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/30/2025	12/29/2024	9/29/2024	6/30/2024	3/31/2024	12/31/2023	10/1/2023	7/2/2023	4/2/2023	1/1/2023	10/2/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.39%	5.26%	5.25%	4.31%	2.34%	70.51%	6.78%	-10.41%	-10.81%	28.45%	-14.32%
EBITDA Growth	187.12%	-12.67%	-25.92%	-8.93%	776.44%	54.47%	1.57%	7.58%	-92.03%	33.63%	19.19%
EBIT Growth	285.25%	-18.88%	-35.67%	-9.26%	375.33%	91.61%	-0.75%	6.59%	-121.76%	87.39%	31.56%
NOPAT Growth	-3.68%	-11.93%	-11.06%	3.24%	30.55%	50.81%	3.51%	-1.23%	-21.43%	33.47%	-18.77%
Net Income Growth	237.91%	-15.26%	-89.65%	-8.90%	4,886.76%	15.03%	483.85%	6.86%	-101.32%	-25.68%	21.57%
EPS Growth	238.81%	-10.76%	-89.13%	-1.53%	4,566.67%	19.70%	507.74%	8.89%	-101.55%	-25.42%	22.63%
Operating Cash Flow Growth	14.14%	-11.19%	6.73%	34.70%	12.28%	46.97%	19.18%	-25.07%	-18.15%	-6.66%	-24.20%
Free Cash Flow Firm Growth	-147.66%	-387.49%	-651.44%	190.99%	291.51%	-64.31%	-110.26%	-290.41%	-516.64%	601.04%	40.92%
Invested Capital Growth	18.27%	11.20%	10.27%	-6.37%	-15.34%	2.40%	7.02%	22.41%	18.07%	-3.61%	-0.89%
Revenue Q/Q Growth	-2.78%	0.22%	0.11%	4.98%	-0.06%	0.21%	-0.78%	2.99%	66.51%	-37.25%	-16.75%
EBITDA Q/Q Growth	170.88%	10.89%	-31.33%	39.19%	-17.61%	-5.93%	-15.58%	1,239.54%	-85.48%	-38.15%	-10.58%
EBIT Q/Q Growth	260.75%	15.56%	-42.40%	60.43%	-24.04%	-8.36%	-18.75%	586.80%	-152.87%	-52.53%	-12.75%
NOPAT Q/Q Growth	57.77%	-22.22%	-20.55%	-1.20%	44.25%	-21.46%	-7.77%	24.93%	66.64%	-46.09%	-11.99%
Net Income Q/Q Growth	220.58%	27.36%	-42.51%	43.96%	-19.61%	-84.44%	405.99%	7,664.71%	-101.93%	-21.04%	-7.40%
EPS Q/Q Growth	221.99%	27.03%	-42.49%	44.03%	-15.19%	-84.53%	420.92%	6,633.33%	-102.27%	-21.43%	-6.67%
Operating Cash Flow Q/Q Growth	-40.23%	-12.64%	41.90%	54.03%	-53.49%	4.99%	79.08%	28.40%	-39.12%	-14.86%	12.60%
Free Cash Flow Firm Q/Q Growth	-74.06%	-34.60%	-135.31%	-42.39%	949.86%	451.81%	95.72%	-21.25%	-295.65%	1.18%	-20.67%
Invested Capital Q/Q Growth	9.54%	-2.35%	-2.22%	13.07%	3.00%	-3.17%	-16.97%	2.23%	24.58%	1.20%	-5.03%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	66.40%	68.35%	69.01%	69.40%	69.55%	68.23%	69.06%	69.97%	68.00%	76.83%	69.13%
EBITDA Margin	69.77%	25.04%	22.63%	32.99%	24.88%	30.18%	32.15%	37.79%	2.91%	33.31%	33.80%
Operating Margin	28.24%	15.91%	22.42%	27.96%	27.63%	19.60%	25.92%	27.01%	27.12%	22.48%	26.50%
EBIT Margin	61.68%	16.62%	14.41%	25.05%	16.39%	21.57%	23.58%	28.80%	-6.09%	19.19%	25.37%
Profit (Net Income) Margin	50.24%	15.24%	11.99%	20.88%	15.22%	18.93%	121.91%	23.90%	-0.33%	28.05%	22.29%
Tax Burden Percent	80.69%	88.27%	80.71%	81.52%	87.64%	83.90%	498.91%	81.57%	5.28%	141.65%	86.19%
Interest Burden Percent	100.95%	103.85%	103.06%	102.22%	105.96%	104.59%	103.61%	101.76%	101.10%	103.20%	101.95%
Effective Tax Rate	19.31%	11.73%	19.29%	18.48%	12.36%	14.38%	17.40%	14.75%	0.00%	15.61%	16.67%
Return on Invested Capital (ROIC)	24.09%	15.71%	19.44%	21.80%	24.56%	19.23%	21.76%	20.32%	17.41%	20.29%	23.40%
ROIC Less NNEP Spread (ROIC-NNEP)	81.65%	18.62%	6.89%	19.20%	10.83%	49.63%	1,006.48%	22.52%	-17.14%	-163.20%	33.04%
Return on Net Nonoperating Assets (RNNOA)	11.51%	2.46%	1.07%	4.30%	2.15%	1.03%	30.08%	2.52%	-2.75%	1.34%	0.20%
Return on Equity (ROE)	35.60%	18.17%	20.50%	26.09%	26.72%	20.26%	51.83%	22.85%	14.66%	21.63%	23.60%
Cash Return on Invested Capital (CROIC)	3.71%	11.48%	12.21%	26.90%	38.23%	22.88%	16.67%	0.40%	4.10%	26.23%	23.18%
Operating Return on Assets (OROA)	30.14%	8.49%	7.34%	11.64%	7.63%	10.35%	10.55%	11.69%	-2.52%	8.31%	11.06%
Return on Assets (ROA)	24.55%	7.78%	6.11%	9.70%	7.09%	9.08%	54.53%	9.70%	-0.13%	12.15%	9.72%
Return on Common Equity (ROCE)	35.60%	18.17%	20.50%	25.87%	26.72%	20.26%	51.83%	22.66%	14.66%	21.63%	23.60%
Return on Equity Simple (ROE_SIMPLE)	27.92%	0.00%	20.93%	53.14%	54.95%	0.00%	48.61%	17.37%	17.95%	0.00%	25.68%
Net Operating Profit after Tax (NOPAT)	4,988	3,162	4,065	5,116	5,179	3,590	4,571	4,956	3,967	2,381	4,416
NOPAT Margin	22.79%	14.04%	18.09%	22.79%	24.22%	16.78%	21.41%	23.03%	18.99%	18.97%	22.08%
Net Nonoperating Expense Percent (NNEP)	-57.56%	-2.91%	12.54%	2.60%	13.73%	-30.40%	-984.73%	-2.20%	34.55%	183.49%	-9.64%
Return On Investment Capital (ROIC_SIMPLE)	3.83%	2.92%	-	-	-	3.66%	-	-	-	2.04%	-
Cost of Revenue to Revenue	33.60%	31.65%	30.99%	30.60%	30.45%	31.77%	30.94%	30.03%	32.00%	23.17%	30.87%
SG&A Expenses to Revenue	23.35%	28.65%	24.38%	25.31%	24.59%	27.16%	25.29%	25.08%	23.48%	24.76%	24.88%
R&D to Revenue	14.73%	23.60%	22.04%	16.19%	16.56%	21.21%	17.11%	17.21%	16.77%	29.15%	17.43%
Operating Expenses to Revenue	38.16%	52.44%	46.60%	41.44%	41.92%	48.63%	43.14%	42.96%	40.87%	54.35%	42.63%
Earnings before Interest and Taxes (EBIT)	13,503	3,743	3,239	5,623	3,505	4,614	5,035	6,197	-1,273	2,408	5,073
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	15,275	5,639	5,085	7,405	5,320	6,457	6,864	8,131	607	4,180	6,758
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.05	4.89	5.54	4.92	5.39	5.32	5.51	5.55	5.48	5.66	5.47
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	4,727.39	0.00	0.00	191.57	463.37
Price to Revenue (P/Rev)	4.41	3.93	4.43	4.06	4.41	4.29	5.14	5.56	5.02	5.43	5.28
Price to Earnings (P/E)	18.07	24.83	26.46	9.25	9.82	10.40	11.33	31.95	30.53	24.22	21.29
Dividend Yield	3.03%	3.39%	3.01%	3.29%	3.03%	3.09%	3.07%	2.85%	3.03%	2.68%	2.82%
Earnings Yield	5.53%	4.03%	3.78%	10.81%	10.19%	9.61%	8.82%	3.13%	3.28%	4.13%	4.70%
Enterprise Value to Invested Capital (EV/IC)	4.45	4.32	4.72	4.20	4.97	4.95	5.14	4.66	4.47	6.15	5.59
Enterprise Value to Revenue (EV/Rev)	4.56	4.07	4.61	4.25	4.50	4.37	5.23	5.81	5.28	5.65	5.25
Enterprise Value to EBITDA (EV/EBITDA)	12.20	15.41	16.65	14.12	14.39	16.87	20.16	22.13	21.41	17.30	16.19
Enterprise Value to EBIT (EV/EBIT)	15.61	22.43	23.79	19.59	19.90	25.54	32.25	35.10	34.03	23.60	22.51
Enterprise Value to NOPAT (EV/NOPAT)	23.59	20.61	22.52	19.98	21.10	19.83	22.65	24.94	23.42	26.78	24.98
Enterprise Value to Operating Cash Flow (EV/OCF)	16.45	14.89	16.07	14.92	16.61	16.33	19.67	22.83	19.98	21.32	18.80
Enterprise Value to Free Cash Flow (EV/FCFF)	130.11	39.65	40.53	15.10	11.93	21.89	31.87	1,280.64	118.03	23.03	24.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.67	0.51	0.51	0.58	0.48	0.43	0.42	0.60	0.75	0.52	0.43
Long-Term Debt to Equity	0.49	0.43	0.45	0.44	0.36	0.38	0.37	0.44	0.49	0.35	0.37
Financial Leverage	0.14	0.13	0.15	0.22	0.20	0.02	0.03	0.11	0.16	-0.01	0.01
Leverage Ratio	2.47	2.48	2.44	2.52	2.61	2.44	2.34	2.42	2.57	2.45	2.45
Compound Leverage Factor	2.49	2.57	2.51	2.58	2.77	2.55	2.42	2.46	2.60	2.53	2.49
Debt to Total Capital	40.08%	33.88%	33.76%	36.71%	32.45%	29.90%	29.58%	37.38%	42.74%	34.04%	30.04%
Short-Term Debt to Total Capital	10.66%	5.53%	4.21%	8.72%	8.25%	3.52%	3.83%	9.59%	14.53%	10.95%	4.15%
Long-Term Debt to Total Capital	29.42%	28.35%	29.54%	27.99%	24.20%	26.38%	25.76%	27.79%	28.22%	23.09%	25.89%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.03%	0.00%	0.00%	0.00%
Common Equity to Total Capital	59.92%	66.12%	66.24%	63.29%	67.55%	70.10%	70.42%	61.59%	57.26%	65.96%	69.96%
Debt to EBITDA	1.56	1.56	1.47	1.59	1.26	1.33	1.51	2.32	2.77	1.52	1.28
Net Debt to EBITDA	0.40	0.52	0.64	0.61	0.28	0.29	0.32	0.87	1.08	0.66	-0.08
Long-Term Debt to EBITDA	1.15	1.31	1.29	1.21	0.94	1.17	1.32	1.72	1.83	1.03	1.10
Debt to NOPAT	3.02	2.09	1.99	2.25	1.84	1.56	1.70	2.61	3.03	2.35	1.97
Net Debt to NOPAT	0.78	0.69	0.86	0.87	0.41	0.34	0.36	0.98	1.18	1.03	-0.13
Long-Term Debt to NOPAT	2.22	1.75	1.74	1.72	1.37	1.38	1.48	1.94	2.00	1.59	1.70
Altman Z-Score	4.00	3.74	3.94	3.73	4.10	4.16	4.40	3.65	3.15	3.78	4.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.85%	0.00%	0.00%	0.00%	0.82%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.26	1.11	1.03	1.07	1.17	1.16	1.21	1.12	1.07	0.99	1.43
Quick Ratio	0.96	0.78	0.70	0.77	0.84	0.82	0.86	0.84	0.68	0.65	1.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-9,158	-5,261	-3,909	11,068	19,213	1,830	-520	-12,164	-10,032	5,128	5,068
Operating Cash Flow to CapEx	808.91%	447.63%	816.45%	918.92%	612.56%	535.63%	885.22%	399.05%	395.75%	391.65%	665.68%
Free Cash Flow to Firm to Interest Expense	-44.89	-38.40	-20.25	40.99	123.95	12.12	-2.71	-56.06	-47.32	28.97	99.37
Operating Cash Flow to Interest Expense	20.46	50.97	41.41	20.86	23.59	52.07	39.01	19.27	15.36	30.23	123.22
Operating Cash Flow Less CapEx to Interest Expense	17.93	39.58	36.34	18.59	19.74	42.35	34.60	14.44	11.48	22.51	104.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.49	0.51	0.51	0.46	0.47	0.48	0.45	0.41	0.41	0.43	0.44
Accounts Receivable Turnover	5.77	5.98	5.66	5.32	5.47	5.89	4.97	4.55	4.85	5.46	5.01
Inventory Turnover	2.36	2.33	2.28	2.14	2.18	2.48	1.98	1.83	1.99	2.38	2.10
Fixed Asset Turnover	4.41	4.40	4.46	4.29	4.30	4.50	4.13	3.85	3.99	4.33	4.22
Accounts Payable Turnover	3.20	2.76	3.14	2.78	2.92	2.72	2.45	2.20	2.46	2.35	2.43
Days Sales Outstanding (DSO)	63.26	61.06	64.45	68.66	66.69	61.96	73.39	80.14	75.26	66.90	72.80
Days Inventory Outstanding (DIO)	154.95	156.95	160.04	170.73	167.38	147.42	184.20	199.72	183.38	153.26	173.62
Days Payable Outstanding (DPO)	114.20	132.49	116.39	131.44	125.11	134.17	149.05	165.92	148.08	155.40	150.42
Cash Conversion Cycle (CCC)	104.01	85.52	108.11	107.95	108.95	75.21	108.54	113.94	110.56	64.75	96.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	91,580	83,602	85,612	87,554	77,434	75,179	77,638	93,506	91,468	73,419	72,547
Invested Capital Turnover	1.06	1.12	1.07	0.96	1.01	1.15	1.02	0.88	0.92	1.07	1.06
Increase / (Decrease) in Invested Capital	14,146	8,423	7,974	-5,952	-14,034	1,760	5,091	17,120	13,999	-2,747	-652
Enterprise Value (EV)	407,622	361,338	403,983	367,776	385,168	372,143	398,784	435,442	409,079	451,852	405,711
Market Capitalization	394,151	349,226	388,529	351,760	377,754	365,738	392,374	417,085	388,480	434,491	407,763
Book Value per Share	$32.44	$29.69	$29.14	$29.72	$29.08	$28.57	$27.41	$28.92	$27.21	$29.38	$28.37
Tangible Book Value per Share	($1.29)	($4.29)	($5.87)	($5.17)	($0.37)	($0.81)	$0.03	($6.36)	($8.51)	$0.87	$0.33
Total Capital	130,361	108,124	105,909	113,029	103,652	98,106	101,149	122,011	123,776	116,446	106,626
Total Debt	52,252	36,634	35,751	41,491	33,632	29,332	29,921	45,602	52,907	39,642	32,027
Total Long-Term Debt	38,355	30,651	31,289	31,636	25,082	25,881	26,051	33,901	34,928	26,886	27,603
Net Debt	13,471	12,112	15,454	16,016	7,414	6,405	6,410	17,097	20,599	17,361	-2,052
Capital Expenditures (CapEx)	516	1,560	979	613	597	1,468	846	1,048	823	1,366	944
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-10,236	-12,967	-14,345	-11,736	-9,391	-12,263	-10,308	-10,407	-10,314	-10,033	-9,962
Debt-free Net Working Capital (DFNWC)	28,545	11,555	5,952	13,739	16,827	10,664	13,203	18,098	21,994	12,248	24,117
Net Working Capital (NWC)	14,648	5,572	1,490	3,884	8,277	7,213	9,333	6,397	4,015	-508	19,693
Net Nonoperating Expense (NNE)	-6,011	-269	1,371	430	1,924	-459	-21,457	-188	4,035	-1,139	-42
Net Nonoperating Obligations (NNO)	13,471	12,112	15,454	16,016	7,414	6,405	6,410	17,097	20,599	-3,385	-2,052
Total Depreciation and Amortization (D&A)	1,772	1,896	1,846	1,782	1,815	1,843	1,829	1,934	1,880	1,772	1,685
Debt-free, Cash-free Net Working Capital to Revenue	-11.46%	-14.60%	-16.36%	-13.56%	-10.96%	-14.40%	-13.51%	-13.88%	-13.32%	-12.54%	-12.90%
Debt-free Net Working Capital to Revenue	31.95%	13.01%	6.79%	15.87%	19.65%	12.52%	17.30%	24.14%	28.39%	15.31%	31.24%
Net Working Capital to Revenue	16.40%	6.27%	1.70%	4.49%	9.66%	8.47%	12.23%	8.53%	5.18%	-0.64%	25.51%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$4.57	$1.42	$1.12	$1.95	$1.35	$1.61	$10.32	$1.98	($0.03)	$1.34	$1.70
Adjusted Weighted Average Basic Shares Outstanding	2.41B	2.41B	2.41B	2.41B	2.41B	2.53B	2.52B	2.60B	2.61B	2.63B	2.63B
Adjusted Diluted Earnings per Share	$4.54	$1.41	$1.11	$1.93	$1.34	$1.58	$10.21	$1.96	($0.03)	$1.32	$1.68
Adjusted Weighted Average Diluted Shares Outstanding	2.42B	2.43B	2.43B	2.42B	2.43B	2.56B	2.55B	2.63B	2.61B	2.66B	2.66B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B	2.41B	2.60B	2.60B	2.60B	2.61B
Normalized Net Operating Profit after Tax (NOPAT)	5,002	3,199	4,098	5,106	5,322	3,638	4,701	5,079	4,058	2,427	4,470
Normalized NOPAT Margin	22.85%	14.20%	18.24%	22.75%	24.89%	17.00%	22.02%	23.60%	19.42%	19.34%	22.35%
Pre Tax Income Margin	62.26%	17.26%	14.85%	25.61%	17.37%	22.56%	24.43%	29.30%	-6.16%	19.80%	25.87%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	66.19	27.32	16.78	20.83	22.61	30.56	26.22	28.56	-6.00	13.60	99.47
NOPAT to Interest Expense	24.45	23.08	21.06	18.95	33.41	23.78	23.81	22.84	18.71	13.45	86.59
EBIT Less CapEx to Interest Expense	63.66	15.93	11.71	18.56	18.76	20.83	21.82	23.73	-9.89	5.89	80.96
NOPAT Less CapEx to Interest Expense	21.92	11.69	15.99	16.68	29.56	14.05	19.40	18.01	14.83	5.73	68.08
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	54.76%	84.05%	79.71%	30.49%	30.40%	33.48%	34.25%	91.60%	93.03%	65.11%	60.13%
Augmented Payout Ratio	68.90%	101.34%	95.82%	37.71%	38.18%	47.86%	52.04%	148.31%	155.86%	98.75%	89.94%

Frequently Asked Questions About Johnson & Johnson's Financials

When does Johnson & Johnson's financial year end?

According to the most recent income statement we have on file, Johnson & Johnson's fiscal year ends in December. Their fiscal year 2024 ended on December 29, 2024.

How has Johnson & Johnson's net income changed over the last 9 years?

Johnson & Johnson's net income appears to be on an upward trend, with a most recent value of $14.07 billion in 2024, falling from $15.41 billion in 2015. The previous period was $35.15 billion in 2023. See where experts think Johnson & Johnson is headed by visiting Johnson & Johnson's forecast page.

What is Johnson & Johnson's operating income?

Johnson & Johnson's total operating income in 2024 was $20.80 billion, based on the following breakdown:

Total Gross Profit: $61.35 billion
Total Operating Expenses: $40.55 billion

How has Johnson & Johnson revenue changed over the last 9 years?

Over the last 9 years, Johnson & Johnson's total revenue changed from $70.07 billion in 2015 to $88.82 billion in 2024, a change of 26.8%.

How much debt does Johnson & Johnson have?

Johnson & Johnson's total liabilities were at $108.61 billion at the end of 2024, a 10.0% increase from 2023, and a 74.4% increase since 2015.

How much cash does Johnson & Johnson have?

In the past 9 years, Johnson & Johnson's cash and equivalents has ranged from $12.89 billion in 2022 to $24.11 billion in 2024, and is currently $24.11 billion as of their latest financial filing in 2024.

How has Johnson & Johnson's book value per share changed over the last 9 years?

Over the last 9 years, Johnson & Johnson's book value per share changed from 25.71 in 2015 to 29.69 in 2024, a change of 15.5%.

Related Companies

This page (NYSE:JNJ) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Financials

Frequently Asked Questions About Johnson & Johnson's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Johnson & Johnson (JNJ) Financials

Annual Income Statements for Johnson & Johnson

Quarterly Income Statements for Johnson & Johnson

Annual Cash Flow Statements for Johnson & Johnson

Quarterly Cash Flow Statements for Johnson & Johnson

Annual Balance Sheets for Johnson & Johnson

Quarterly Balance Sheets for Johnson & Johnson

Annual Metrics And Ratios for Johnson & Johnson

Quarterly Metrics And Ratios for Johnson & Johnson

Frequently Asked Questions About Johnson & Johnson's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools